Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

20/20 Global, Inc. PsyTech the World's Most Recognized Psychedelic Conference to Host Live Webinar on New Approaches to Ketamine-Assisted Treatment Wednesday, January 27th 2021 at 12:00 EST


An online Ketamine roundtable event for Psychedelic experts, investors and enthusiasts

MIAMI, Jan. 26, 2021 (GLOBE NEWSWIRE) -- 20/20 Global, Inc., (OTC Pink: TWGL) (the “Company”) announced today an upcoming complimentary Psychedelic Industry webinar for investors and interested individuals. The webinar is produced by PsyTech and titled “Progressive Applications of Ketamine - The Spearhead of Psychedelic Therapy.” Participants can expect a discussion on new approaches to ketamine-assisted treatment with the leading practitioners in the field. Participants will hear from the expert psychiatrists, anesthesiologists, and psychotherapists at the forefront of innovative – and highly impactful – therapeutic ketamine treatments.


The virtual investor webinar is open to individual investors, institutional investors, advisors, analysts and the Psychedelic Community. The program opens at 12:00 PM ET on Wednesday, January 27 th . The webinar will be moderated by Mark Braunstein DO - Founder and CEO Reconscious Medical

Speakers for the PsyTech Virtual Investor Conference include:

Julane Andries, LMFT - Senior Psychotherapist Center for Transformational Psychotherapy

Phil Wolfson MD - CEO Non-Profit Ketamine Research Foundation

Steven L. Mandel MD - Founder & President Ketamine Clinics Los Angeles

Abid Nazeer MD Founder and President Aps Ketamine

Casey A. Paleos MD -Science Director Mindbloom

There are no fees to log-in, or attend the live presentations.


20/20 Global through Mycotopia Therapies owns 10% of PsyTech. Ehave, Inc. (EHVVF) controls approximately 75.77% of the outstanding shares of 20/20 Global. 20/20 Global Inc. plans to file with FINRA to change the name of the company to Mycotopia Therapy. Ehave will continue develop Ketadash, the Ehave Dashboard, its MegaTeam video game applications for children with ADHD, the safety and security of Electronic Health Records (EHRs), improving mental health, and combatting mental illness.

About 20/20 Global and Mycotopia Therapy

Mycotopia Therapy focuses on helping you heal and reclaim your life. Your journey of healing is an understanding of the causes and works to mental wellness through psychedelic enhanced psychotherapy, integrated with a professional team of mental wellness practitioners and cutting-edge technology. Psychedelic therapy is a holistic and spiritual approach providing healing and has shown successful treatment for many years. Additional information on Mycotopia Therapy can be found on the Company’s website at: .

Forward-Looking Statement Disclaimer

This press release contains “forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995. Such statements may be preceded by the words
“intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company’s research, manufacturing and other development efforts; (ii) the Company’s ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company’s products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company’s industry and introduction of competing products; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading "Risk Factors" in 20/20 Global, Inc.’s Registration
Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on
September 24, 2015, as amended, which is available on the SEC's website,

Contact for 20/20 Global and Ehave

Media Inquiries: Gabe Rodriguez


Investor Relations:


Phone: (623) 261-9046